Certara adds 4 new leaders to its Simcyp division

By Emily Bader
Princeton | Apr 18, 2019 at 10:24 am

Certara, a Princeton-based drug development solutions company, announced Wednesday four senior executive appointments in its Simcyp division.

Simcyp, it said, is a provider of mechanistic modeling technology for drug development.

Rob Aspbury has joined Simcyp as chief operating officer, Certara said, as well as Frederic Yves Boi being named the division’s new senior scientific advisor and head of mechanistic modeling; Will Redfern as vice president, quantitative systems toxicology and safety; and Noriko Okudaira as senior consultant/scientific advisor.

“I am delighted to welcome Rob, Frederic, Will and Noriko to the Simcyp team. It is a testament to the major scientific and technological advances that Simcyp continues to make that we are able to attract staff of this caliber,” Steve Toon, Simcyp president and managing director. “Focusing on safety and efficacy, the team will build on Simcyp’s position, delivering confidence in drug development, drug target selection, and drug label enrichment.”

Aspbury has more than 17 years of commercial and scientific leadership experience. He was previously named global finance director at Covance‘s Clinical Pharmacology Services Division, then was named to managing director, then vice president, Europe, and later vice president and general manager, global. His most recent appointment was vice president of Covance Strategic Solutions, Biosimilars.

Prior to Certara, Bois was previously research director of the French National Institute for Industrial Environment and Risks. He also has spent time as professor and chair of mathematical modeling for systems toxicology at UTC and INERIS.

Emily Bader | ebader@roi-nj.com | emilybader